Hdm2 negatively regulates telomerase activity by functioning as an E3 ligase of hTERT

Oncogene

Volumn 29, Issue 28, 2010, Pages 4101-4112

  Oh, W ^a,c   Lee, E W ^a   Lee, D ^a   Yang, M R ^a   Ko, A ^a   Yoon, C H ^a   Lee, H W ^b   Bae, Y S ^a   Choi, C Y ^a   Song, J ^a  

^a Sungkyunkwan University   (South Korea)

^b Yonsei University   (South Korea)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Hdm2; hTERT; p53; telomerase; ubiquitination

Indexed keywords

ARGININE; DOXORUBICIN; LYSINE; PROTEIN MDM2; TELOMERASE REVERSE TRANSCRIPTASE; UBIQUITIN PROTEIN LIGASE E3;

AMINO TERMINAL SEQUENCE; APOPTOSIS; ARTICLE; CELL PROTECTION; CELL STRAIN HCT116; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MUTANT; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN STABILITY; UBIQUITINATION;

CELL LINE, TUMOR; HUMANS; IMMUNOPRECIPITATION; LYSINE; PROTO-ONCOGENE PROTEINS C-MDM2; TELOMERASE; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 77954759082     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.160     Document Type: Article

References (44)

1. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N et al. (2002). Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62: 3876-3882.
2. Blackburn EH. (2000). The end of the (DNA) line. Nat Struct Biol 7: 847-850.
3. Blasco MA. (2003). Telomeres and cancer: a tale with many endings. Curr Opin Genet Dev 13: 70-76.
4. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB et al. (1998). Extension of life-span by introduction of telomerase into normal human cells. Science 279: 349-352.
5. Bouska A, Eischen CM. (2009). Murine double minute 2: p53-independent roads lead to genome instability or death. Trends Biochem Sci 34: 279-286.
6. Brooks CL, Gu W. (2006). p53 ubiquitination: Mdm2 and beyond. Mol Cell 21: 307-315.
7. Cairney CJ, Keith WN. (2008). Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie 90: 13-23.
8. Camus S, Menendez S, Cheok CF, Stevenson LF, Lain S, Lane DP. (2007). Ubiquitin-independent degradation of p53 mediated by high-risk human papillomavirus protein E6. Oncogene 26: 4059-4070.
9. Cao Y, Li H, Deb S, Liu JP. (2002). TERT regulates cell survival independent of telomerase enzymatic activity. Oncogene 21: 3130-3138.
10. Carroll VA, Ashcroft M. (2008). Regulation of angiogenic factors by HDM2 in renal cell carcinoma. Cancer Res 68: 545-552.
11. Cong Y, Shay JW. (2008). Actions of human telomerase beyond telomeres. Cell Res 18: 725-732.
12. Cong YS, Wright WE, Shay JW. (2002). Human telomerase and its regulation. Microbiol Mol Biol Rev 66: 407-425. table of contents.
13. Counter CM, Meyerson M, Eaton EN, Ellisen LW, Caddle SD, Haber DA et al. (1998). Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase. Oncogene 16: 1217-1222.
14. Dairkee SH, Nicolau M, Sayeed A, Champion S, Ji Y, Moore DH et al. (2007). Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome. Oncogene 26: 6269-6279.
15. Dalla Torre CA, Maciel RM, Pinheiro NA, Andrade JA, De Toledo SR, Villa LL et al. (2002). TRAP-silver staining, a highly sensitive assay for measuring telomerase activity in tumor tissue and cell lines. Braz J Med Biol Res 35: 65-68.
16. de Lange T. (2005). Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev 19: 2100-2110.
17. Dimri GP, Martinez JL, Jacobs JJ, Keblusek P, Itahana K, Van Lohuizen M et al. (2002). The Bmi-1 oncogene induces telomerase activity and immortalizes human mammary epithelial cells. Cancer Res 62: 4736-4745.
18. Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. (2009). MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 15: 171-183.
19. Froment P, Dupont J, Christophe-Marine J. (2008). Mdm2 exerts pro-apoptotic activities by antagonizing insulin-like growth factor-I-mediated survival. Cell Cycle 7: 3098-3103.
20. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. (1999). Creation of human tumour cells with defined genetic elements. Nature 400: 464-468.
21. Harley CB. (2008). Telomerase and cancer therapeutics. Nat Rev Cancer 8: 167-179.
22. Kanaya T, Kyo S, Hamada K, Takakura M, Kitagawa Y, Harada H et al. (2000). Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription. Clin Cancer Res 6: 1239-1247.
23. Kim JH, Park SM, Kang MR, Oh SY, Lee TH, Müller MT et al. (2005). Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev 19: 776-781.
24. Kim NW, Wu F. (1997). Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP). Nucleic Acids Res 25: 25952597.
25. Kusumoto M, Ogawa T, Mizumoto K, Ueno H, Niiyama H, Sato N, et al. (1999). Adenovirus-mediated p53 gene transduction inhibits telomerase activity independent of its effects on cell cycle arrest and apoptosis in human pancreatic cancer cells. Clin Cancer Res 5: 2140-2147.
26. Kyo S, Takakura M, Taira T, Kanaya T, Itoh H, Yutsudo M et al. (2000). Sp1 cooperates with c-Myc to activate transcription of the human telomerase reverse transcriptase gene (hTERT). Nucleic Acids Res 28: 669677.
27. Luiten RM, Pene J, Yssel H, Spits H. (2003). Ectopic hTERT expression extends the life span of human CD4+ helper and regulatory T-cell clones and confers resistance to oxidative stressinduced apoptosis. Blood 101: 45124519.
28. Maser RS, DePinho RA. (2002). Connecting chromosomes, crisis, and cancer. Science 297: 565-569.
29. McEachern MJ, Krauskopf A, Blackburn EH. (2000). Telomeres and their control. Annu Rev Genet 34: 331-358.
30. Oh W, Ghim J, Lee EW, Yang MR, Kim ET, Ahn JH et al. (2009). PML-IV functions as a negative regulator of telomerase by interacting with TERT. J Cell Sci 122: 2613-2622.
31. Oh W, Lee EW, Sung YH, Yang MR, Ghim J, Lee HW et al. (2006). Jab1 induces the cytoplasmic localization and degradation of p53 in coordination with Hdm2. J Biol Chem 281: 17457-17465.
32. Rahman R, Latonen L, Wiman KG. (2005). hTERT antagonizes p53-induced apoptosis independently of telomerase activity. Oncogene 24: 1320-1327.
33. Roth A, Yssel H, Pene J, Chavez EA, Schertzer M, Lansdorp PM et al. (2003).Telomerase levels control the lifespan of human T lymphocytes. Blood 102: 849-857.
34. Saller E, Tom E, Brunori M, Otter M, Estreicher A, Mack DH et al. (1999). Increased apoptosis induction by 121F mutant p53. EMBO J 18: 4424-4437.
35. Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R et al. (2004). p53-dependent down-regulation of telomerase is mediated by p21waf1. J Biol Chem 279: 50976-50985.
36. Teng L, Specht MC, Barden CB, Fahey III TJ. (2003). Antisense hTERT inhibits thyroid cancer cell growth. J Clin Endocrinol Metab 88: 1362-1366.
37. Urquidi V, Tarin D, Goodison S. (2000). Role of telomerase in cell senescence and oncogenesis. Annu Rev Med 51: 65-79.
38. Vaziri H, Benchimol S. (1998). Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span. Curr Biol 8: 279-282.
39. Veldman T, Horikawa I, Barrett JC, Schlegel R. (2001). Transcrip-tional activation of the telomerase hTERT gene by human papillomavirus type 16 E6 oncoprotein. J Virol 75: 4467-4472.
40. Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH et al. (2009). p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol 11: 694-704.
41. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I et al. (2006). Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 119: 2797-2806.
42. Xu D, Wang Q, Gruber A, Bjorkholm M, Chen Z, Zaid A et al. (2000). Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene 19: 5123-5133.
43. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. (1999). Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev 13: 2388-2399.
44. Zhang Z, Zhang R. (2005). p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets 5: 9-20.